BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 37091139)

  • 1. Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment.
    Matamala Montoya M; van Slobbe GJJ; Chang JC; Zaal EA; Berkers CR
    Front Oncol; 2023; 13():1155621. PubMed ID: 37091139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
    Zaal EA; Wu W; Jansen G; Zweegman S; Cloos J; Berkers CR
    Cancer Metab; 2017; 5():7. PubMed ID: 28855983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.
    Markovina S; Callander NS; O'Connor SL; Xu G; Shi Y; Leith CP; Kim K; Trivedi P; Kim J; Hematti P; Miyamoto S
    Mol Cancer; 2010 Jul; 9():176. PubMed ID: 20604947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
    Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
    Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
    Mark C; Warrick J; Callander NS; Hematti P; Miyamoto S
    Mol Cancer Res; 2022 Sep; 20(9):1456-1466. PubMed ID: 35604822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
    Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
    J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma.
    Zaal EA; de Grooth HJ; Oudaert I; Langerhorst P; Levantovsky S; van Slobbe GJJ; Jansen JWA; Menu E; Wu W; Berkers CR
    Mol Omics; 2022 Jan; 18(1):19-30. PubMed ID: 34879122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
    Abdi J; Mutis T; Garssen J; Redegeld FA
    PLoS One; 2014; 9(5):e96608. PubMed ID: 24794258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
    Schwestermann J; Besse A; Driessen C; Besse L
    Front Oncol; 2022; 12():899272. PubMed ID: 35692781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche.
    Solimando AG; Malerba E; Leone P; Prete M; Terragna C; Cavo M; Racanelli V
    Front Oncol; 2022; 12():973836. PubMed ID: 36212502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
    Gebraad A; Ohlsbom R; Miettinen JJ; Emeh P; Pakarinen TK; Manninen M; Eskelinen A; Kuismanen K; Slipicevic A; Lehmann F; Nupponen NN; Heckman CA; Miettinen S
    Cells; 2022 May; 11(9):. PubMed ID: 35563880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
    Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
    Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
    Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
    J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
    Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W
    Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.
    Colombo M; Garavelli S; Mazzola M; Platonova N; Giannandrea D; Colella R; Apicella L; Lancellotti M; Lesma E; Ancona S; Palano MT; Barbieri M; Taiana E; Lazzari E; Basile A; Turrini M; Pistocchi A; Neri A; Chiaramonte R
    Haematologica; 2020 Jul; 105(7):1925-1936. PubMed ID: 31582544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
    Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
    Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
    Tibullo D; Giallongo C; Romano A; Vicario N; Barbato A; Puglisi F; Parenti R; Amorini AM; Wissam Saab M; Tavazzi B; Mangione R; Brundo MV; Lazzarino G; Palumbo GA; Volti GL; Raimondo FD; Lazzarino G
    Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.